Suggested remit: To appraise the clinical and cost effectiveness of aumolertinib within its marketing authorisation for treating epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small-cell lung cancer that has not previously been treated.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 4000

Project Team

Project lead Celia Mayers

Email enquiries

Stakeholders

Companies sponsors EQRx (aumolertinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups EGFR Positive UK
  Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies • Accord Healthcare (gefitinib) (confidentiality agreement not signed, not participating)
  • AstraZeneca (gefitinib, osimertinib)
  • Boehringer Ingelheim (afatinib) (confidentiality agreement not signed, not participating)
  • Cipla EU (gefitinib) (confidentiality agreement not signed, not participating)
  • Genus Pharmaceuticals (gefitinib) (confidentiality agreement not signed, not participating)
  • Glenmark Pharmaceuticals Europe (erlotinib, gefitinib) (confidentiality agreement not signed, not participating)
  • Mylan (erlotinib) (confidentiality agreement not signed, not participating)
  • Pfizer (dacomitinib)
  • Roche (erlotinib) (confidentiality agreement not signed, not participating)
  • Sandoz (erlotinib, gefitinib) (confidentiality agreement not signed, not participating) (confidentiality agreement not signed, not participating)
  • Tillomed Laboratories (erlotinib) (confidentiality agreement not signed, not participating)
  • Zentiva (erlotinib, gefitinib) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
01 December 2021 Invitation to participate
06 October 2021 - 27 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual